Disease/Infection News

RSS

Research shows anti-microbial medications lead to acute liver failure

New research shows that anti-microbial medications are a common cause of drug-induced liver injury (DILI) leading to acute liver failure (ALF), with women and minorities disproportionately affected.

1 Dec 2010

Goosby, Emanuel address progress, potential roadblocks ahead for introduction of microbicides in developing countries

The growing evidence supporting the promise of new HIV prevention products, like microbicides, requires that groups start planning now for how best to roll-out prevention interventions in the future, U.S. Global AIDS Coordinator Eric Goosby and Special Advisor on Health Policy to the Director of the White House Office of Management and Budget Ezekiel Emanuel said Monday during a USAID Microbicide Stakeholders Meeting in Washington.

30 Nov 2010

Argos commences dosing in Arcelis personalized immunotherapy Phase 2b clinical trial for HIV

Argos Therapeutics today announced that it has initiated dosing of patients in a Phase 2b clinical trial of its Arcelis™ personalized immunotherapy for the treatment of HIV patients, AGS-004.

30 Nov 2010

Opinions: Obama's Global Fund pledge; harm reduction in Iran; HIV prevention; African development

There are some encouraging signs in the epic battle against AIDS and HIV infections. But those bright spots dim considerably in the face of the fact that about 7,100 people a day become infected.

30 Nov 2010

HIV testing rates rise among Americans

A U.S. government report released Tuesday says that a record number of Americans are getting tested for HIV but more than 200,000 Americans are infected and are unaware of their status. In 2009 82.9 million adults age 18 to 64 had been tested for HIV. This is 11.4 million more than the total in 2006. Also until 2009 45 percent of adults had been tested at least once in their lives, up from 40 percent four years ago. However 55 percent of adults, and 28.3 percent of adults at risk for HIV, have never been tested, according to the report.

30 Nov 2010

Gavi Alliance elects new chair to continue global immunisation efforts

Former Norwegian Minister of Health and current member of parliament Dagfinn Høybråten was unanimously elected by the GAVI Alliance Board as its new Chair, GAVI announced on the first day of its board meeting taking place in Kigali, the capital of Rwanda.

30 Nov 2010

Canadians at increased risk for flu complications not aware of all the facts

It starts with a headache, chills or that all-over-achy feeling. It comes on quickly, yet too many Canadians ignore the rapid onset of flu symptoms. But for the millions of Canadians at increased risk for developing serious complications from the flu, including people 65 and older, pregnant women and those with chronic medical conditions like chronic obstructive pulmonary disease (COPD), asthma, heart disease and diabetes, this 'laissez faire' attitude could be putting their health in jeopardy.

30 Nov 2010

Pharmasset commences combination study of PSI-7977 and PSI-938 nucleotide analogs in HCV

Pharmasset, Inc. announced today that dosing has begun in Part 2 of a Phase 1 study. This is the first clinical study combining a purine (PSI-938) and a pyrimidine (PSI-7977) nucleotide analog for HCV, and is designed to evaluate once daily doses of PSI-7977 and PSI-938 in patients with HCV who have not been treated previously.

30 Nov 2010

AIDS Healthcare Foundation to participate in Members Project

AIDS Healthcare Foundation (AHF) is proud to be selected as a candidate charity in Members Project, a partnership between American Express and TakePart.

30 Nov 2010

Emergency artesunate suppositories are cost-effective intervention for children with suspected severe malaria

Giving emergency artesunate suppositories to children with suspected severe malaria before referring them for treatment is a cost-effective intervention that can substantially improve the management of childhood malaria in remote African settings, according to a new study led by Boston University School of Public Health [BUSPH] researcher Yesim Tozan, PhD.

30 Nov 2010

American Red Cross announces additional $2 million to combat cholera epidemic in Haiti

The American Red Cross announced today it is committing an additional $2 million to combat an escalating cholera epidemic in Haiti that has killed more than 1,700 people and sickened more than 75,000.

30 Nov 2010

GeoVax supports Bionor's Phase 2b trial of therapeutic HIV/AIDS vaccine

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), announced it was pleased to learn of the partial success observed in the recently completed Phase 2b trial of a therapeutic HIV/AIDS vaccine produced by Bionor Immuno AS of Oslo, Norway.

30 Nov 2010

New study may lead to non-medicinal methods of eradicating Hamburger disease

Hamburger disease, a debilitating form of food poisoning, may be a thing of the past. New findings from an international research collaboration conducted by the French National Institute for Agronomic Research (INRA), involving the Universit- de Montr-al are the first to show how the contaminating E.coli bacterium is able to survive in the competitive environment of a cow's intestine by scavenging specific food sources.

30 Nov 2010

International Harm Reduction Conference to focus on HIV/AIDS epidemic

Injecting drug use and growing HIV/AIDS epidemic in Middle East and North Africa region to be focus of the International Harm Reduction conference taking place in Beirut, Lebanon April 3-7 2011

30 Nov 2010

DTRA presents Outstanding Scientific Achievement award to Aduro BioTech

Aduro BioTech, a clinical-stage immunotherapy company, is pleased to announce the "Outstanding Scientific Achievement" award from the Defense Threat Reduction Agency. The award was presented at the 2010 Chemical and Biological Defense Science and Technology Conference in Orlando, Florida to Dr. Justin Skoble, Associate Director, Biodefense and Process Development at Aduro BioTech.

30 Nov 2010

RCSI researchers discover potential new target for diarrhoea associated intestinal diseases

A study by researchers in the Royal College of Surgeons in Ireland (RCSI) has uncovered a potential new target for the treatment of a range of intestinal diseases that are associated with diarrhoea. Current medications are often ineffective and can have serious side effects so this discovery gives hope for the development of new treatments for sufferers of intestinal disease.

30 Nov 2010

Sanofi Pasteur commences phase II clinical study of vaccine for Clostridium difficile infection prevention

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has started its phase II clinical study of a vaccine for primary prevention of Clostridium difficile infection (CDI). The trial starting in the United States is focused on evaluating prevention of the first episode of CDI in at-risk individuals, which includes adults with imminent hospitalization or current or impending residence in a long-term care or rehabilitation facility.

30 Nov 2010

Scientists uncover new regulatory mechanism in body's response to eliminate pathogens

A team of scientists from The Scripps Research Institute have uncovered a previously unknown regulatory mechanism in the body's response to eliminate pathogens, such as bacteria and viruses. The findings challenge a long-held dogma in the field of immunology and have potential implications for far-ranging topics from how vaccines should be administered to the origin of autoimmunity.

30 Nov 2010

University of Adelaide researcher leads collaboration for universal flu vaccine

A University of Adelaide researcher is leading a collaboration between Australia and Indonesia on the production of a universal flu vaccine. The frequent arising of new influenza strains represents the greatest challenge to health authorities as it renders currently available vaccines ineffective, says Dr Mohammed Alsharifi, the Head of the Vaccine Research Group at the School of Molecular and Biomedical Science, University of Adelaide.

30 Nov 2010

NIAID scientists confirm antiviral activity of two lead compounds against HPV

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds showed excellent in vitro antiviral activity and no cellular toxicity at dose levels tested for Human Papillomavirus (HPV).

30 Nov 2010

Disease/Infection News

Research shows anti-microbial medications lead to acute liver failure

Goosby, Emanuel address progress, potential roadblocks ahead for introduction of microbicides in developing countries

Argos commences dosing in Arcelis personalized immunotherapy Phase 2b clinical trial for HIV

Opinions: Obama's Global Fund pledge; harm reduction in Iran; HIV prevention; African development

HIV testing rates rise among Americans

Gavi Alliance elects new chair to continue global immunisation efforts

Canadians at increased risk for flu complications not aware of all the facts

Pharmasset commences combination study of PSI-7977 and PSI-938 nucleotide analogs in HCV

AIDS Healthcare Foundation to participate in Members Project

Emergency artesunate suppositories are cost-effective intervention for children with suspected severe malaria

American Red Cross announces additional $2 million to combat cholera epidemic in Haiti

GeoVax supports Bionor's Phase 2b trial of therapeutic HIV/AIDS vaccine

New study may lead to non-medicinal methods of eradicating Hamburger disease

International Harm Reduction Conference to focus on HIV/AIDS epidemic

DTRA presents Outstanding Scientific Achievement award to Aduro BioTech

RCSI researchers discover potential new target for diarrhoea associated intestinal diseases

Sanofi Pasteur commences phase II clinical study of vaccine for Clostridium difficile infection prevention

Scientists uncover new regulatory mechanism in body's response to eliminate pathogens

University of Adelaide researcher leads collaboration for universal flu vaccine

NIAID scientists confirm antiviral activity of two lead compounds against HPV

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News